Passage Bio, Inc. (PASG)

1.3100 -0.0300 (-2.24%) At close: 04:00PM EDT

Passage Bio, Inc.

One Commerce Square
39th Floor 2005 Market Street
Philadelphia, PA 19103
United States
267 866 0311
https://www.passagebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 58

Key executives

Name	Title	Pay	Exercised	Year born
Dr. William Chou M.D.	President, CEO & Director	945.73k	N/A	1974
Mr. Edgar B. Cale Esq., J.D.	General Counsel & Company Secretary	804.69k	N/A	1964
Dr. Mark Forman M.D., Ph.D.	Chief Medical Officer	866.31k	N/A	1964
Dr. James M. Wilson M.D., Ph.D.	Co-Founder & Chief Scientific Advisor	N/A	N/A	1955
Ms. Kathleen Borthwick	Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1977
Mr. Stuart M. Henderson	Senior Vice President of Corporate Development & Investor Relations	N/A	N/A	N/A
Eden Fucci	Senior Vice President of Technical Operations	N/A	N/A	N/A
Dr. Sue Browne Ph.D.	Senior Vice President of Research & Development	N/A	N/A	N/A
Dr. Karl Whitney Ph.D.	Senior Vice President of Global Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Corporate governance

Passage Bio, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.